Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 4, 2011, Pages 317-324

  Barhoover, Melissa A ^a   Kalafatis, Michael ^a,b,c  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

activated protein C; Arg306; Arg506; cleavage sites; factor Va; mutation

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; PROTHROMBIN; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME ACTIVITY; MUTATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; WILD TYPE;

ANIMALS; ARGININE; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; COS CELLS; FACTOR VA; HUMANS; KINETICS; PLASMIDS; POINT MUTATION; PROTEIN BINDING; PROTEIN C; RECOMBINANT PROTEINS; THROMBOPLASTIN; TRANSFECTION;

EID: 79955950241     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283456c4e     Document Type: Article

References (38)

1. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101:20-30. (Pubitemid 36025882)
2. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254:10952-10962. (Pubitemid 10163282)
3. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477:349-360. (Pubitemid 30119912)
4. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981; 78:2249-2252. (Pubitemid 11119893)
5. Kalafatis M, Egan JO, van?t Veer C, Cawthern KM, Mann KG. The regulation of clotting factors. Crit Rev Eukaryot Gene Expr 1997; 7:241-280. (Pubitemid 28101329)
6. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87:4708-4717. (Pubitemid 26162370)
7. Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265:1688-1692.
8. Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem 1992; 267:13246-13250.
9. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269:31869-31880. (Pubitemid 24379561)
10. Bakker HM, Tans G, Janssen-Claessen T, Thomassen MC, Hemker HC, Griffin JH, Rosing J. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208:171-178.
11. Kalafatis M, Mann KG. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 1993; 268:27246-27257. (Pubitemid 24006444)
12. Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270:21158-21166.
13. Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 1997; 272:20678-20683. (Pubitemid 27355631)
14. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270:4053-4057.
15. Kalafatis M, Haley PE, Lu D, Bertina RM, Long GL, Mann KG. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood 1996; 87:4695-4707. (Pubitemid 26162369)
16. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76:208-214. (Pubitemid 26285253)
17. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91:1135-1139. (Pubitemid 28086864)
18. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood 1998; 91:1140-1144. (Pubitemid 28086865)
19. Norstr?m E, Thorelli E, Dahlbäck B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood 2002; 100:524-530. (Pubitemid 34761115)
20. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Tans G, Rosing J, Bertina RM. Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg306, Arg506, and Arg679. J Biol Chem 2004; 279:6567-6575. (Pubitemid 38248793)
21. Tran S, Dahlbäck B. Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S. J Thromb Haemost 2010; 8:129-136.
22. Dirven RJ, Vos HL, Bertina RM. The R306G and R506Q mutations in coagulation factor V reveals additional cleavage sites for activated protein C in the R313-R321 region and at R505. Thromb Res 2010; 125:444-450.
23. Erdogan E, Bukys MA, Kalafatis M. The contribution of amino acid residues 1508-1515 of factor V to light chain generation. J Thromb Haemost 2008; 6:118-124.
24. Erdogan E, Bukys MA, Orfeo T, Mann KG, Kalafatis M. Identification of an inactivating cleavage site for a-thrombin on the heavy chain of factor Va. Thromb Haemost 2007; 98:998-1006. (Pubitemid 350091128)
25. Singh LS, Bukys MA, Beck DO, Kalafatis M. Amino acids Glu323, Tyr324, Glu330, and Val331 of factor Va heavy chain are essential for expression of cofactor activity. J Biol Chem 2003; 278:28335-28345. (Pubitemid 36900035)
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
27. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350-4354. (Pubitemid 9256559)
28. Bukys MA, Blum MA, Kim PY, Brufatto N, Nesheim ME, Kalafatis M. Incorporation of factor Va into prothrombinase is required for coordinated cleavage of prothrombin by factor Xa. J Biol Chem 2005; 280:27393-27401. (Pubitemid 41040781)
29. Bukys MA, Kim PY, Nesheim ME, Kalafatis M. A control switch for prothrombinase: characterization of a hirudin-like pentapeptide from the COOH terminus of factor Va heavy chain that regulates the rate and pathway for prothrombin activation. J Biol Chem 2006; 281:39194-39204. (Pubitemid 46041879)
30. Krishnaswamy S, Williams EB, Mann KG. The binding of activated protein C to factors V and Va. J Biol Chem 1986; 261:9684-9693. (Pubitemid 17214094)
31. Luckow EA, Lyons DA, Ridgeway TM, Esmon CT, Laue TM. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: analysis by analytical ultracentrifugation. Biochemistry 1989; 28:2348-2354. (Pubitemid 19084465)
32. Guinto ER, Esmon CT. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984; 259:13986-13992. (Pubitemid 15222833)
33. Hockin MF, Cawthern KM, Kalafatis M, Mann KG. A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. Biochemistry 1999; 38:6918-6934.
34. Suzuki K, Stenflo J, Dahlback B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258:1914-1920. (Pubitemid 13101396)
35. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67. (Pubitemid 24144355)
36. Rosendaal FR, Koster T, Vandenbrouke JP, Reitsma PH. High risk thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-1508.
37. Egan JO, Kalafatis M, Mann KG. The effect of Arg306-Ala and Arg506-Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci 1997; 6:2016-2027. (Pubitemid 27391282)
38. Franco RF, Maffei FH, Lourenco D, Morelli V, Thomazini IA, Piccinato CE, et al. Factor V Arg306 Thr (factor V Cambridge) and factor V Arg306 toGly mutations in venous thrombotic disease. Br J Haematol 1998; 103:888-890. (Pubitemid 28545336)